Inicio › Sarcoma del tejido blando › Texas
Ensayos clínicos de Sarcoma del tejido blando en Texas
37 estudios sobre Sarcoma del tejido blando buscan participantes en Texas.
Ciudades en Texas
Texto oficial del estudio (inglés)
Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma
- UT MD Anderson Cancer Center, Houston
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 29 sept 2026 · NCT06498648A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
- The University of Texas Southwestern Medical Center - Harold C Simmons Comprehensive Cancer Center, Dallas
- Baylor College of Medicine, Houston
ReclutandoFase 1/2
Hasta los 25 · Todos los sexos · Actualizado el 25 sept 2026 · NCT04094610DESTINY-PANTUMOUR04
- Research Site, Dallas
ReclutandoEstudio observacional
Edades de 18 a 130 · Todos los sexos · Actualizado el 25 sept 2026 · NCT07124000Anti-GD2 ADC M3554 in Advanced Solid Tumors
- The University of Texas MD Anderson Cancer Center, Houston
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 22 sept 2026 · NCT06641908A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors
- The University of Texas MD Anderson Cancer Center, Houston
- NEXT Oncology, San Antonio
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 18 sept 2026 · NCT07705334First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma
- University Of Texas MD Anderson Cancer Center, Houston
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 11 sept 2026 · NCT06797999Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
- The University of Texas MD Anderson Cancer Center, Houston
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 8 sept 2026 · NCT05732831Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
- UT MD Anderson Cancer Center, Houston
ReclutandoFase 1
Edades de 12 a 85 · Todos los sexos · Actualizado el 8 sept 2026 · NCT03715933Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma
- UT MD Anderson Cancer Center, Houston
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 4 sept 2026 · NCT05711615A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- The University of Texas MD Anderson Cancer Center - Texas Medical Center, Houston
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 3 sept 2026 · NCT06760819Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- The Don and Sybil Harrington Cancer Center, Amarillo
- UT MD Anderson Cancer Center, Houston
- Audie L Murphy VA Hospital, San Antonio
ReclutandoEstudio observacionalSe aceptan voluntarios sanos
Edades de 40 a 75 · Todos los sexos · Actualizado el 2 sept 2026 · NCT05334069Actinium Therapy for Late-stage Aggressive Sarcomas
- MD Anderson Cancer Center, Houston
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 28 ago 2026 · NCT07156565STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas
- MD Anderson Cancer Center, Houston
- NEXT Houston, Houston
- NEXT Dallas, Irving
- y 2 más
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 25 ago 2026 · NCT06975293Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program
- M D Anderson Cancer Center, Houston
ReclutandoEstudio observacional
Todas las edades · Todos los sexos · Actualizado el 21 ago 2026 · NCT01772771Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced/Metastatic Soft-tissue Sarcoma
- MD Anderson Cancer Center, Houston
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 20 ago 2026 · NCT07283731T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy (attIL12-TIL) for Advanced/Metastatic Soft Tissue and Bone Sarcoma Patients.
- MD Anderson Cancer Center, Houston
ReclutandoFase 1
Edades de 12 en adelante · Todos los sexos · Actualizado el 18 ago 2026 · NCT06474676Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM)
- Ut Southwestern Medical Center, Dallas
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 17 ago 2026 · NCT07139990A Study of MGC026 in Participants With Advanced Solid Tumors
- The University of Texas MD Anderson Cancer Center, Houston
- University of Texas Health Science Center at Houston, Houston
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 11 ago 2026 · NCT06242470Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma
- M D Anderson Cancer Center, Houston
Reclutando
Edades de 10 en adelante · Todos los sexos · Actualizado el 11 ago 2026 · NCT04199026A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue Sarcomas
- The University of Texas M. D. Anderson Cancer Center, Houston
ReclutandoFase 1
Edades de 1 a 30 · Todos los sexos · Actualizado el 6 ago 2026 · NCT07444619IDOV-Immune for Advanced Solid Tumors
- MD Anderson Cancer Center, Houston
- South Texas Accelerated Research Therapeutics, San Antonio
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 5 ago 2026 · NCT06910657Prospective Study Evaluating the Treatment Outcomes for Localised Recurrent, Resectable Retroperitoneal Liposarcoma
- MD Anderson Cancer Center, Houston
ReclutandoEstudio observacional
Edades de 18 en adelante · Todos los sexos · Actualizado el 15 jul 2026 · NCT07377747Lead-212 PSV359 Therapy for Patients With Solid Tumors
- MD Anderson Cancer Center, Houston
ReclutandoFase 1/2
Edades de 18 a 90 · Todos los sexos · Actualizado el 6 jul 2026 · NCT06710756Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors
- M D Anderson Cancer Center, Houston
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 11 jun 2026 · NCT04771520A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
- MD Anderson Cancer Center, Houston
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 11 jun 2026 · NCT06789172A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
- UT Southwestern Medical Center, Dallas
- MD Anderson Cancer Center, Houston
ReclutandoFase 1/2
Edades de 12 en adelante · Todos los sexos · Actualizado el 27 may 2026 · NCT03093116Iscador® P (Mistletoe) Immunotherapy for Recurrent Resectable Osteogenic Sarcoma
- M.D. Anderson Children's Cancer Hospital, Houston
ReclutandoFase 2
Edades de 8 a 30 · Todos los sexos · Actualizado el 22 may 2026 · NCT05726383SATURN-STS: Phase II Study of Neoadjuvant Atezolizumab With Doxorubicin, Concurrent Atezolizumab With Pre-operative Radiation Therapy and Adjuvant Atezolizumab in Patients With High-risk Surgically Resectable Extremity and Truncal Soft Tissue Sarcoma
- The University of Texas M. D. Anderson Cancer Center, Houston
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 22 may 2026 · NCT07049848A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours
- University of Texas MD Anderson Cancer Center, Houston
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 15 may 2026 · NCT04969835Study Assessing the Effects of Early Psychiatric Referral on Mental Health and Quality of Life in People With Sarcoma
- William Beaumont Army Medical Center, Fort Bliss
Reclutando
Edades de 18 en adelante · Todos los sexos · Actualizado el 15 may 2026 · NCT06129903Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial
- M D Anderson Cancer Center, Houston
Reclutando
Edades de 18 en adelante · Todos los sexos · Actualizado el 15 abr 2026 · NCT04693377Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma
- Children's Health Dallas, Dallas
- The University of Texas MD Anderson Cancer Center, Houston
ReclutandoFase 1/2
Edades de 2 a 30 · Todos los sexos · Actualizado el 3 feb 2026 · NCT05734066HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma
- Texas Children's Hospital, Houston
ReclutandoFase 1
Edades de 1 a 25 · Todos los sexos · Actualizado el 22 ene 2026 · NCT04995003cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
- Elligo Health Research, Inc., Austin
ReclutandoEstudio observacionalSe aceptan voluntarios sanos
Edades de 40 en adelante · Todos los sexos · Actualizado el 20 ene 2026 · NCT05366881A Study of MT-4561 in Patients With Various Advanced Solid Tumors
- The University of Texas MD Anderson Cancer Center, Houston
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 11 dic 2025 · NCT06943521A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
- Mary Crowley Cancer Research, Dallas
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 8 oct 2025 · NCT04370587BostonGene and Exigent Genomic INsight Study
- Oncology Consultants, Houston
ReclutandoEstudio observacional
Edades de 18 en adelante · Todos los sexos · Actualizado el 17 feb 2025 · NCT06272864De ClinicalTrials.gov, datos obtenidos el 30 sept 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.